We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Intranasal Stimulator Increases Tear Production

By HospiMedica International staff writers
Posted on 09 May 2017
Print article
Image: The TrueTear neurostimulation device is designed to induce tearing (Photo courtesy of Allergan).
Image: The TrueTear neurostimulation device is designed to induce tearing (Photo courtesy of Allergan).
A noninvasive, handheld device delivers neurostimulation to the nasal cavity via disposable tips in order to increase tear production.

The TrueTear intranasal tear neurostimulator consists of a rechargeable handheld unit and disposable hydrogel tips, which are inserted into the nasal passage and used to stimulate the trigeminal nerve via the afferent ethmoid nasal pathway. The neurostimulation device allows dry eye patients not only to treat themselves by activating their own tear production system, but also to activate other glands that secrete lipids and proteins, thus increasing the mucin and aqueous layers of the tear film.

Two clinical studies involving 145 aqueous deficient dry eye adult patients showed positive safety and effectiveness of the device in the increase of tear production. The direct clinical benefit of temporarily increasing tear production as a therapy for dry eye disease was not assessed as part of the clinical trials, but all device-related adverse events were mild in nature. The TrueTear intranasal tear neurostimulator is a product of Allergan, and has been approved by the U.S. Food and Drug Administration (FDA).

“TrueTear represents a technological breakthrough for eye care professionals as it delivers an effective, non-invasive and drug-free way to temporarily increase tear production,” said David Nicholson, chief R&D officer at Allergan. “As an innovator in eye care, we are continually looking for new products to offer through our portfolio, and TrueTear represents the next step forward.”

“In clinical trials, TrueTear demonstrated increased tear production upon stimulation of the nasal cavity,” said professor of ophthalmology John Sheppard, MD, MSc, of Eastern Virginia Medical School (Norfolk, USA). “Interestingly, neurostimulation has been used as an approach for a wide variety of disorders for more than 30 years. TrueTear is the first of its kind to provide a temporary increase in tear production in this way.”

Of more than 100 million dry eye sufferers worldwide, about 80% suffer from evaporative dry eye, caused by meibomian gland dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The condition leaves patients with too few tears, making the remaining ones feel too salty. Symptoms of evaporative dry eye disease include eye irritation, dryness, redness, tiredness, and visual disturbances.

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Medical Gas Blender
BlenderBuddy 1

Print article

Channels

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.